The case is set for the students from the MBA in Merger and Acquisition or related courses. Sanofi-Aventis was considering to finalize its offer terms for the acquisition of Genzyme in January 2011. The market potential of a drug in Genzyme’s pipeline, alemtuzumab, and how early Genzyme could overcome the defects present in its manufacturing, both would play a significant role in valuation of this M&A.
To overcome the differences in the estimation set by each party, consultants asked for an up-front cash payment and a contingent value right (CVR). Would a CVR prove to be helpful to minimize the valuation gap?
Related Case Solutions & Analyses:
Seven Disciplines for Venturing in China
Zenglibao: An Internet Money Market Fund Run by Tianhong Asset Management Co., Ltd.
Bank of America Analysis
Blue Ocean Finance: The Evolution of Corporate Treasury Operations in the 21st Century
Landmark Facility Solutions
The Gold Story
Equity-Worthiness and Equity-Willingness: Key Factors In Private Equity Deals
Apogee Health Care
Show Me the Money (A)
Barrington High School
